Jerzy Lewandowski

Jerzy Lewandowski

Jerzy Lewandowski is a senior markets editor at TS2.tech. His coverage ranges from stocks and semiconductors to AI and the broader global markets. He studied economics at the University of Warsaw and worked in investment analysis before becoming a financial journalist. Follow Jerzy Lewandowski on Google News.

Rackspace Q2 Sales Beat Forecasts; Margin Challenges Remain as AI Transition Continues

Rackspace Q2 Sales Beat Forecasts; Margin Challenges Remain as AI Transition Continues

Rackspace Technology posted second-quarter revenue that topped its initial guidance range. However, the cloud firm maintained its previously lowered forecast from July. The outcome puts investors in a position to balance an earlier-than-expected sales gain with expenses tied to its move towards enterprise AI.
Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing

Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing

NEW YORK, Aug. 10, 2026, 4:06 p.m. EDT — Silence Therapeutics plc jumped over 25% in late trading on Monday as the company reported its investigational RNA-interference drug divesiran reached all primary and secondary endpoints in a randomized Phase 2 polycythemia vera trial. While overall efficacy was notable, investors appeared to focus on a less obvious outcome: the therapy showed sustained activity with dosing every 12 weeks.
1 4 5 6 7 8 38